Innova Captab Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹450Cr
- +42.4% YoY
- +18.4% QoQ
- Net profit
- ₹42Cr
- +23.5% YoY
- +40% QoQ
- Margin
- 15%
- 0 pp YoY
- +1 pp QoQ
Guidance rank: #12 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
The short version
Overall business growth targeted at 20%+ year-on-year (Vinay Lohariwala, Q3 FY26 call). Innova Captab projects a sustained overall growth of 20%+ year-on-year at the organization level, driven significantly by ramp-up at the Jammu facility for the next 2-3 years.
From Innova Captab Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Overall business growth targeted at 20%+ year-on-year (Vinay Lohariwala, Q3 FY26 call).
- Jammu facility expected to drive 20%+ growth for the next 2-3 years with revenues ramping up from Rs. 89 crores in Q3 FY26 towards a potential Rs. 1,400 crores at optimum capacity (Lokesh Bhasin, Vinay Lohariwala).
- Jammu offers significant room for scaling beyond FY28-29, with future growth strategies in development (Vinay Lohariwala).
- Branded generics projected to sustain growth around 20%+ annually over the next 2-3 years, supported by domestic and international expansion (Vinay Lohariwala, Lokesh Bhasin).
2 more points from Innova Captab Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Innova Captab Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Innova Captab is focused on ramping up the Jammu facility, which started commercial production in January 2025 and is expected to drive 20%+ overall business growth for the next 2-3 years.
- Jammu facility has potential revenue capacity of Rs. 1,400+ crores at 65-75% utilization.
- The company is actively working on future growth strategies beyond FY28-29 to identify new growth engines and will inform the market once plans are finalized.
2 more points from Innova Captab Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Innova Captab Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Innova Captab Ltd said on order book & pipeline — free account, 30 seconds.
Innova Captab Ltd — Quarterly revenue & net profit
Innova Captab Ltd Q3 FY26 results — key figures
| ₹ Cr | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 450 | 316 | +42.4% | 380 | +18.4% |
| Operating profit (EBITDA) | 69 | 47 | +46.8% | 52 | +32.7% |
| Operating margin | 15% | 15% | 0 pp | 14% | +1 pp |
| Profit before tax | 56 | 46 | +21.7% | 39 | +43.6% |
| Net profit (PAT) | 42 | 34 | +23.5% | 30 | +40% |
| EPS (₹) | 7.37 | 5.98 | +23.2% | 5.18 | +42.3% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹496 Cr, net profit ₹42 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Innova Captab's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Natural Capsules (Q3 FY26)
Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks
- Wanbury (Q3 FY26)
Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against
- Gujarat Themis Biosyn (Q3 FY26)
43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against
- Balaxi Pharma (Q3 FY26)
Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Innova Captab Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Innova Captab Ltd Q3 FY26 results?
Overall business growth targeted at 20%+ year-on-year (Vinay Lohariwala, Q3 FY26 call). Innova Captab projects a sustained overall growth of 20%+ year-on-year at the organization level, driven significantly by ramp-up at the Jammu facility for the next 2-3 years.
What is Innova Captab Ltd share price analysis?
Innova Captab Ltd currently shows a neutral. The stock trades at a P/E of 38.5 with a market cap of ₹5,408 Cr. Investors should review the full earnings analysis for detailed insights.
Is Innova Captab Ltd planning capital expenditure?
Innova Captab is focused on ramping up the Jammu facility, which started commercial production in January 2025 and is expected to drive 20%+ overall business growth for the next 2-3 years.
Keep Innova Captab Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
